𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease

✍ Scribed by Waclaw S. Adamus; Joachim P. Leonard; Wolfgang Tröger

Book ID
118347256
Publisher
Elsevier Science
Year
1995
Tongue
English
Weight
668 KB
Volume
56
Category
Article
ISSN
0024-3205

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

WAL 2014 FU (talsaclidine): A preferenti
WAL 2014 FU (talsaclidine): A preferentially neuron activating muscarinic agonist for the treatment of Alzheimer's disease
✍ Helmut A. Ensinger; Wolf-Dieter Bechtel; Franz W. Birke; Klaus D. Mendla; Joachi 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB 👁 2 views

The functional selectivity of WAL 2014 FU with regard to stimulation of the neuronal muscarinic M 1 receptor subtype in vitro and in vivo is shown in different receptor preparations, isolated organ models, whole animal testing, and finally humans. From receptor binding experiments in membrane prepar

Xanomeline: A selective muscarinic agoni
Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease
✍ Frank P. Bymaster; Celia A. Whitesitt; Harlan E. Shannon; Neil DeLapp; John S. W 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 3 views

Xanomeline is a novel muscarinic receptor agonist relatively devoid of parasympathomimetic side effects. Xanomeline had high affinity for muscarinic receptors and much lower affinity for a variety of other neuronal receptors in radioligand binding assays. Functional studies in cell lines transfected